GCG and early-onset autosomal dominant Alzheimer disease: GLP-1 has emerged as a prominent therapeutic target for type 2 diabetes mellitus (T2DM) and obesity and has recently been shown to have potential therapeutic effects on comorbidities in these populations, such as autoimmune processes, chronic kidney disease (CKD), cardiovascular disease, and Alzheimer’s disease [10].